KKL-40 是一种小分子抑制剂,专门针对反式转录过程,能够有效抑制甲氧西林敏感和耐药的金黄色葡萄球菌 (S. aureus),以及包括耐万古霉素的屎肠球菌、枯草芽孢杆菌和化脓性链球菌在内的其他革兰氏阳性病原体。KKL-40 与人类抗菌肽 LL-37 协同作用可抑制金黄色葡萄球菌,但与达托霉素、卡那霉素或红霉素等其他抗生素之间没有协同效应。反式转录是一种极端的重新编码形式,KKL-40 能抑制该过程,同时对 HeLa 细胞无毒。
Lytixar is a Synthetic Antimicrobial Peptide, it shows activity against Daptomycin-Nonsusceptible, Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Linezolid-Nonsusceptible Staphylococcus aureus. LTX-109 demonstrated a MIC range o
AFN-1252, also known as AFN-12520000; API-1252; Debio-1452, is FASII Inhibitor which is potentially for the treatment of acute bacterial skin. AFN-1252 exhibits typical MIC(90) values of ≤0·015 μg ml against diverse clinical isolates of S. aureus, oral absorption, long elimination half-live and efficacy in animal models. AFN-1252 efficiently blocked daptomycin-induced phospholipid decoy production, even in the case of isolates resistant to AFN-1252, which prevented the inactivation of daptomycin and resulted in sustained bacterial killing. In turn, daptomycin prevented the fatty acid-dependent emergence of AFN-1252-resistant isolates in vitr